Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options ...

The Company is currently analyzing the case and will update the prescribing information for Elevidys to note this development.

(Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing early investors to ...

Shares of Sarepta Therapeutics Inc. have lost more than 26% this week, heading for their worst such performance in over a ...

Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by analysts at HC Wainwright in ...

In a report released yesterday, Gavin Clark-Gartner from Evercore ISI maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report), ...

AstraZeneca signed a deal with Alteogen worth up to $1.35 billion for subcutaneous cancer drugs. Taiho Pharmacetical bought ...

Sarepta stock may recover sharply as additional information and data reveal that the adverse event reported by the company is ...

After Sarepta reported the death of a patient who had recently taken the gene therapy Elevidys, patient advocacy group Parent ...

Scotiabank lowered the firm’s price target on Sarepta (SRPT) to $80 from $105 and keeps a Sector Perform rating on the shares. After speaking ...

Wednesday’s 10 Top Performers. In this article, we are going to take a look at where Sarepta Therapeutics Inc. (NASDAQ:SRPT) ...